NASDAQ:RZLT Rezolute Q2 2025 Earnings Results & Report $4.87 +0.23 (+4.96%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.87 +0.00 (+0.06%) As of 10/9/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rezolute beat analyst earnings expectations in its Q2 2025 results, released February 12, 2025. The company reported EPS of -$0.22 versus the -$0.33 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateFebruary 12, 2025TimeBefore Market OpensConference Call4:00 PM ET Rezolute EPS ResultsActual EPS-$0.22Consensus EPS -$0.33Beat/MissBeat by +$0.11One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersRezolute Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsRezolute's Q1 2027 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rezolute Q2 2025 Earnings FAQ Did Rezolute beat earnings estimates for Q2 2025? Rezolute (NASDAQ:RZLT) reported earnings of -$0.22 per share for Q2 2025, beating the consensus estimate of -$0.33. The report was announced on Wednesday, February 12, 2025. When is Rezolute's next earnings date? Rezolute's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rezolute on the company's earnings history page. Rezolute Earnings HeadlinesRezolute, Inc. (RZLT) Latest Press Releases & Corporate News - Yahoo FinanceOctober 8 at 6:40 PM | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 8 at 4:29 AM | americanbankingnews.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system. | Banyan Hill Publishing (Ad)Cantor Fitzgerald upgrades Rezolute to overweight from neutralOctober 6, 2026 | msn.comRezolute upgraded at Cantor on pre-BLA meeting for ersodetugOctober 6, 2026 | msn.comRezolute (NASDAQ:RZLT) Stock Price Expected to Rise, Citizens Jmp Analyst SaysOctober 6, 2026 | americanbankingnews.comSee More Rezolute Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rezolute? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rezolute and other key companies, straight to your email. Email Address About RezoluteRezolute (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes. Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar. RZ358 has been evaluated in clinical studies involving children and adults with the condition. The company has also advanced RZ402, an investigational oral plasma kallikrein inhibitor being developed for diabetic macular edema, a vision-threatening complication of diabetes. Rezolute’s pipeline reflects its broader goal of developing treatments that address significant unmet needs in metabolic and related diseases. The company is headquartered in Redwood City, California, and is led by President and Chief Executive Officer Nevan Elam.View Rezolute ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
